Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759787 | 0.96 | NR4A1 (0.45) | NR4A1ALDH1A1FFAR1PLA2G2APLA2G5 | |
| SCHEMBL6761389 | 0.95 | NR4A1 (0.46) | NR4A1ALDH1A1FFAR1PLA2G2APLA2G5 | |
| SCHEMBL6762901 | 0.95 | ESR1 (0.44) | ALDH1A1ESR1TSHRTDP1L3MBTL1 | |
| SCHEMBL6759839 | 0.94 | TSHR (0.45) | ALDH1A1FFAR1PLA2G2APLA2G5ESR1 | |
| SCHEMBL6761346 | 0.92 | FFAR1 (0.44) | NR4A1ALDH1A1FFAR1PLA2G2APLA2G5 | |
| SCHEMBL6762452 | 0.92 | TSHR (0.45) | NR4A1ALDH1A1FFAR1PLA2G2APLA2G5 | |
| SCHEMBL6762751 | 0.91 | NR4A1 (0.44) | NR4A1ALDH1A1FFAR1PLA2G2APLA2G5 | |
| SCHEMBL6763970 | 0.91 | FFAR1 (0.46) | NR4A1ALDH1A1FFAR1PLA2G2APLA2G5 | |
| SCHEMBL6766053 | 0.91 | ESR1 (0.46) | NR4A1ALDH1A1FFAR1PLA2G2APLA2G5 | |
| SCHEMBL6762519 | 0.90 | ALDH1A1 (0.41) | NR4A1ALDH1A1ESR1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | VALENZUELA CORTES CARMEN MARIA (CL) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | PDE3A, PDE3B, PDE12 | NR4A1 1667/4885ALDH1A1 1744/4885FFAR1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.